For this purpose, we extracted signaling pathways that are frequently mutated in bladder cancer patients and demonstrated that combinations with inhibitors targeting RTKs, PI3K-AKT and Ras/MAPK exhibited synergism with Palbociclib. Here, AKT1 is linked to urinary bladder cancer.